⚡ FREE FINANCIAL WORKSPACE
✕
Save to Your Watchlist
Create your free financial workspace to save stocks, track your portfolio, set price alerts, and personalize TickerPulse for your financial goals.
Free Workspace Unlocks:
✓ Personal Watchlist
✓ Real-Time Price Alerts
✓ Portfolio Tracking
✓ Financial Health Score
✓ Personalized AI Copilot
✓ Cross-Device Sync
AS
ASTRAZENECA PHARMA IND LT
NSE: ASTRAZEN
Healthcare & Pharma • Healthcare & Pharma Operations • ISIN: N/A
₹6,669.00
▼ -95.50 (-0.51%)
Data updated: Just now (NSE India Live Feed)
52W Low:
₹6,600.00
Today High / Low:
₹6,753.00 / ₹6,655.00
52W High:
₹9,849.50
Volume:
1,996
🎯
TickerPulse Confluence Engine
Institutional 360°
360° Quantitative Confluence Radar
DEFENSIVE QUALITY COMPOUNDER
Robust balance sheet and strong institutional sponsorship. Favorable for swing accumulation with standard 1% risk discipline.
Confluence Score
Moderate Edge
71
Valuation & Multiples
68/100
P/E, P/B, FCF yield vs historical levels
Trend & Moving Averages
40/100
20/50 EMA structure, RSI momentum, 52W range
Institutional Sponsorship
85/100
FII & DII holdings, delivery turnover backing
Balance Sheet Solvency
87/100
Debt-to-equity ratio, Altman Z score, operating margin
Asymmetric Reward-to-Risk
85/100
Calculated 12.66:1 potential target vs swing low stop
📐 Institutional Trade Setup
1% Risk Aligned
Entry Reference
₹6,669.00
Structural Stop Loss
₹6,402.24
Max Risk: -4%
Technical Target 1
₹10,046.49
Payoff Profile
12.66 : 1.0
Reward-to-Risk
Transparent Business & Valuation Scoring
Methodology v1.0 • Every metric is deterministic and verifiable.
How we calculate scores →
Overall Quality Score
65
/ 100
Moderate
Why this score? ℹ️
Financial Health
80
/ 100
Strong
Why this score? ℹ️
Profitability & Margins
67
/ 100
Moderate
Why this score? ℹ️
Growth Trajectory
40
/ 100
Subdued
Why this score? ℹ️
Valuation Attractiveness
66
/ 100
Moderate
Why this score? ℹ️
Interactive Price Performance & Trend
Live exchange closing feeds from NSE/BSE
1W
1M
6M
1Y
5Y
50-Day DMA:
₹6,435.59
200-Day DMA:
₹5,968.76
14-Day RSI:
50.2 (Neutral)
Trend:
Strong Bullish
Key Fundamentals & Ratios (Data as of 2026-08-31)
Market Cap
₹34,757,500.00L Cr
Large_cap Category
P/E Ratio (TTM)
28.5x
Sector Mean: ~28.5x
Price to Book (P/B)
3.8x
Book Val: ₹0.0
Return on Equity (ROE)
16.4%
Net Profit / Net Worth
ROCE
19.2%
Capital Efficiency
Debt / Equity
0.25
Manageable Leverage
EPS (TTM)
₹243.91
Earnings Per Share
Dividend Yield
0.85%
Annual Cash Payout
Operating Margin
—
Core Operational Spread
Annual Free Cash Flow
₹0.00 Cr
Operating CF minus Capex
Algorithmic Analysis (Pros & Cons)
⚡ Computed from Balance Sheet & Valuation Metrics
✓
Company Strengths (Pros)
•
Company has maintained a healthy low debt-to-equity ratio of 0.25.
•
Delivers solid shareholder returns with an ROE of 16.4%.
⚠
Key Limitations & Risks (Cons)
•
Valuation is sensitive to broader macroeconomic and sectoral interest rate cycles.
Fundamental Health
Piotroski F-Score
7
/ 9
Balance Sheet Score:
Strong Financial Health
Positive Return on Equity (ROE)
✓ PASS
High Capital Efficiency (ROCE > 12%)
✓ PASS
Strong Operating Spread (Margin > 15%)
✗ FAIL
Positive Free Cash Flow Generation
✓ PASS
9-Point Stanford University fundamental screening model.
Solvency & Credit Risk
Altman Z-Score
5.02
Solvency Classification:
Safe Zone (Low Distress)
Firm exhibits exceptionally robust balance sheet solvency with near-zero short-term distress risk.
Safe Zone (>2.99) • Grey Zone (1.81–2.99) • Distress (<1.81)
Valuation Model
Intrinsic Fair Value
DCF + Graham
Estimated Fair Value
₹3,504.02
Premium / Overvalued (-47.5%)
DuPont ROE:
14.4% NPM × 0.85 Turn × 1.25x Lev
Quarterly Financial Performance (Consolidated ₹ Cr)
Past 4 Reported Quarters
Metric (₹ Cr)
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sales / Revenue
₹36,365.03 Cr
₹37,929.12 Cr
₹39,884.23 Cr
₹41,448.32 Cr
Operating Profit
₹6,509.34 Cr
₹6,941.03 Cr
₹7,458.35 Cr
₹7,916.63 Cr
OPM % (Operating Margin)
17.9%
18.3%
18.7%
19.1%
Profit before Tax (PBT)
₹5,207.47 Cr
₹5,552.82 Cr
₹5,966.68 Cr
₹6,333.30 Cr
Net Profit (PAT)
₹3,905.60 Cr
₹4,164.62 Cr
₹4,475.01 Cr
₹4,749.98 Cr
Quarterly EPS (₹)
₹54.41
₹56.75
₹59.67
₹62.01
Shareholding Pattern & Institutional Ownership
Latest Disclosed Quarter
Foreign Institutions (FIIs)
19.80%
Domestic Institutions (DIIs)
15.60%
Technical Levels & Intraday Pivot Matrix
Institutional support, resistance, moving averages & momentum indicators
⚡ Signal: Strong Bullish
RSI (14): 50.2
📈 Key Moving Averages
20 EMA (Short Term)
₹6,588.97
50 SMA (Medium Term)
₹6,435.59
100 SMA (Structural)
₹6,255.52
200 SMA (Long Trend)
₹5,968.76
🎯 52-Week Range Alignment
Distance from 52W High (₹9,849.50)
-32.3%
Distance from 52W Low (₹6,600.00)
+1%
Pivot Model
Support 3
Support 2
Support 1
Central Pivot (P)
Resistance 1
Resistance 2
Resistance 3
Classic Floor
₹6,533.66
₹6,594.33
₹6,631.66
₹6,692.33
₹6,729.66
₹6,790.33
₹6,827.66
Camarilla Intraday
—
L4: ₹6,615.10
L3: ₹6,642.05
₹6,669.00
H3: ₹6,695.95
H4: ₹6,722.90
—
Fibonacci
—
61.8%: ₹6,608.44
38.2%: ₹6,631.56
₹6,692.33
38.2%: ₹6,706.44
61.8%: ₹6,729.56
—
Sector Peers Comparison (Healthcare & Pharma)
Peer Company
Price
Today Change
Market Cap
P/E Ratio
ROE (%)
Compare
NEULANDLAB — NEULAND LAB Ltd.
₹22,665.00
▲ +0.00 (+0.18%)
₹115,050,000.00L Cr
28.5x
16.4%
Compare →
SUNPHARMA — Sun Pharmaceutical Industries Ltd
₹1,867.30
▲ +0.00 (+0.75%)
₹45,100,000.00L Cr
38.4x
17.8%
Compare →
AJANTPHARM — AJANTA PHARMA Ltd
₹3,500.50
▼ 0.00 (-0.24%)
₹18,009,500.00L Cr
28.5x
16.4%
Compare →
GLAXO — GLAXOSMITHKLINE PHARMA LT
₹2,799.90
▼ 0.00 (-1.97%)
₹15,250,500.00L Cr
28.5x
16.4%
Compare →
GLAND — GLAND PHARMA Ltd
₹2,907.80
▲ +0.00 (+2.87%)
₹14,429,000.00L Cr
28.5x
16.4%
Compare →
About ASTRAZENECA PHARMA IND LT
ASTRAZENECA PHARMA IND LT (ASTRAZEN) is an Indian publicly traded enterprise listed on the National Stock Exchange (NSE).
⚠️ Compliance & Research Disclaimer: TickerPulse scores and valuation indicators are model estimates based strictly on publicly disclosed historical financial statements and exchange market data. TickerPulse is not a registered investment advisor and does not provide investment advice or guarantees of future performance. Always consult a certified financial planner before executing market orders.
Execution & Trading Platforms
Looking for an investing platform to trade ASTRAZEN?
Compare SEBI-registered discount brokers by delivery fees, AMC, and platform features.
Compare All Platforms →
Delivery: ₹0 Free • AMC: ₹300 / year
Delivery: ₹20 or 2.5% per trade • AMC: ₹0 Free Maintenance
Investments in securities market are subject to market risks. Read all scheme related documents carefully before investing. AffordOS is an independent research platform and is not a SEBI registered investment adviser. Referral compensation from partner brokers does not influence research scores.
⚖️
SEBI Educational & Quantitative Research Compliance Disclaimer:
TickerPulse is an automated mathematical data analysis and quantitative financial research platform. All market feeds, moving averages, technical pivot levels (Classic, Camarilla, Fibonacci), intrinsic valuation models (DCF, Graham), and quality scores are aggregated strictly for informational and educational purposes. TickerPulse is not a SEBI registered Investment Adviser (RIA) or Research Analyst (RA), and does not provide buy/sell recommendations, stock tips, or guaranteed financial returns. Market investments are subject to market risks. Please read all related documents carefully and consult a certified SEBI-registered financial advisor before trading.
